Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark RCTs in Relapsed/Refractory Multiple Myeloma

CONCLUSIONThe majority of real-world RRMM patients were ineligible for hallmark RCTs. Eligibility rates varied across RCTs, underlining the flawed nature of cross-study comparisons without RCT validation. OS was significantly affected by inability to meet criteria highlighting limited generalizability of RCT results. Greater efforts should be made to broaden eligibility criteria to reflect real-world clinical characteristics to narrow the gap between RCT efficacy and observed effectiveness in real-world MM patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research